Targeting succinate:ubiquinone reductase potentiates the efficacy of anticancer therapy

Biochim Biophys Acta. 2016 Aug;1863(8):2065-71. doi: 10.1016/j.bbamcr.2016.04.026. Epub 2016 Apr 29.

Abstract

Mitochondria play a pivotal role in apoptosis: permeabilization of the outer mitochondrial membrane and the release of pro-apoptotic proteins from the intermembrane space of mitochondria are regarded as the key event in apoptosis induction. Here we demonstrate how non-toxic doses of the mitochondrial Complex II inhibitor thenoyltrifluoroacetone (TTFA), which specifically inhibits the ubiquinone-binding site of succinate dehydrogenase (SDH), synergistically stimulated cell death, induced by harmless doses of cisplatin in a panel of chemoresistant neuroblastoma cell lines. Apoptotic cell death was confirmed by cytochrome c release from the mitochondria, cleavage of poly ADP-ribose polymerase, processing of caspase-3, which is an important executive enzyme in apoptosis, and caspase-3-like activity. Methyl malonate, an inhibitor of the SDHA subunit partially reversed apoptosis stimulated by TTFA in SK-N-BE(2) neuroblastoma cells (NB), indicating that sensitization requires oxidation of succinate. In contrast, in IMR-32 NB cells, the same concentrations of TTFA markedly suppressed cisplatin-induced apoptosis. Comparison of oxygen consumption in cisplatin-resistant SK-N-BE(2) and cisplatin-sensitive IMR-32 cells clearly demonstrated impaired Complex II activity in IMR-32 cells. We also found that in SK-N-BE(2) cells co-treatment with cisplatin and TTFA markedly stimulated formation of reactive oxygen species (ROS), whereas in IMR cells, cisplatin-mediated ROS production was attenuated by TTFA, which explains apoptosis suppression in these cells. Thus, functionally active SDH is a prerequisite for the ROS-mediated sensitization to treatment by TTFA.

Keywords: Apoptosis; Cancer; Mitochondria; Neuroblastoma; Reactive oxygen species; Respiratory chain.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Drug Resistance, Neoplasm
  • Drug Screening Assays, Antitumor
  • Drug Synergism
  • Electron Transport Complex II / antagonists & inhibitors*
  • Humans
  • Mitochondria / drug effects*
  • Mitochondria / enzymology
  • Molecular Targeted Therapy*
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neuroblastoma / pathology
  • Oxidation-Reduction
  • Oxygen Consumption / drug effects
  • Reactive Oxygen Species / metabolism
  • Succinic Acid / metabolism*
  • Superoxides / metabolism
  • Thenoyltrifluoroacetone / pharmacology*

Substances

  • Antineoplastic Agents
  • Neoplasm Proteins
  • Reactive Oxygen Species
  • Superoxides
  • Thenoyltrifluoroacetone
  • Succinic Acid
  • Electron Transport Complex II
  • Cisplatin